Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock: results from the CardShock Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Accepteret manuskript, 1,09 MB, PDF-dokument

  • Antoine Kimmoun
  • Kevin Duarte
  • Veli Pekka Harjola
  • Tuukka Tarvasmäki
  • Bruno Levy
  • Alexandre Mebazaa
  • Sebastien Gibot
  • Katerina Koniari
  • Astrinos Voumvourakis
  • Apostolos Karavidas
  • John Parissis
  • Jordi Sans-Rosello
  • Montserrat Vila
  • Albert Duran-Cambra
  • Alessandro Sionis
  • Jiri Parenica
  • Roman Stipal
  • Ondrej Ludka
  • Marie Palsuva
  • Eva Ganovska
  • Petr Kubena
  • Jindrich Spinar
  • Matias G. Lindholm
  • Hassager, Christian
  • Køber, Lars Valeur
  • Tom Bäcklund
  • Johan Lassus
  • Raija Jurkko
  • Heli Tolppanen
  • Markku S. Nieminen
  • Kristiina Järvinen
  • Tuomo Nieminen
  • Kari Pulkki
  • Leena Soininen
  • Reijo Sund
  • Ilkka Tierala
  • Jukka Tolonen
  • Marjut Varpula
  • Tuomas Korva
  • Mervi Pietilä
  • Anne Pitkälä
  • Rossella Marino
  • Salvatore Di Somma
  • Marco Metra
  • Michela Bulgari
  • Valentina Lazzarini
  • Valentina Carubelli
  • Alexandra Sousa
  • Jose Silva-Cardoso
  • Carla Sousa
  • CardShock Investigators and the GREAT network

Aims: Optimal outcome after cardiogenic shock (CS) depends on a coordinated healing response in which both debris removal and extracellular matrix tissue repair play a crucial role. Excessive inflammation can perpetuate a vicious circle, positioning leucocytes as central protagonists and potential therapeutic targets. High levels of circulating Triggering Receptor Expressed on Myeloid cells-1 (TREM-1), were associated with death in acute myocardial infarction confirming excessive inflammation as determinant of bad outcome. The present study aims to describe the association of soluble TREM-1 with 90-day mortality and with various organ injuries in patients with CS. Methods and results: This is a post-hoc study of CardShock, a prospective, multicenter study assessing the clinical presentation and management in patients with CS. At the time of this study, 87 patients had available plasma samples at either baseline, and/or 48 h and/or 96–120 h for soluble TREM-1 (sTREM-1) measurements. Plasma concentration of sTREM-1 was higher in 90-day non-survivors than survivors at baseline [median: 1392 IQR: (724–2128) vs. 621 (525–1233) pg/mL, p = 0.008), 48 h (p = 0.019) and 96–120 h (p = 0.029). The highest tertile of sTREM-1 at baseline (threshold: 1347 pg/mL) was associated with 90-day mortality with an unadjusted HR 3.08 CI 95% (1.48–6.42). sTREM-1 at baseline was not associated to hemodynamic parameters (heart rate, blood pressure, use of vasopressors or inotropes) but rather with organ injury markers: renal (estimated glomerular filtration rate, p = 0.0002), endothelial (bio-adrenomedullin, p = 0.018), myocardial (Suppression of Tumourigenicity 2, p = 0.002) or hepatic (bilirubin, p = 0.008). Conclusion: In CS patients TREM-1 pathway is highly activated and gives an early prediction of vital organ injuries and outcome. Graphic abstract: [Figure not available: see fulltext.].

OriginalsprogEngelsk
TidsskriftClinical Research in Cardiology
Vol/bind111
Udgave nummer6
Sider (fra-til)604-613
ISSN1861-0684
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The CardShock study was supported by grants from Aarne Koskelo Foundation, the Finnish Cardiac Foundation, and the Finnish State funding for university-level health research.

Publisher Copyright:
© 2021, Springer-Verlag GmbH, DE part of Springer Nature.

ID: 325026013